BIO-Europe Spring® 2017: Biomunex CEO on earlier deals for cancer drugs

April 10, 2017

During the recent BIO-Europe Spring partnering conference in Barcelona, Biomunex CEO Pierre-Emmanuel Gerard chats with Scrip about the company's strategy for partnering with pharmas in the cancer drug development space. He also comments on the recent trend of companies seeking earlier stage deals in cancer drug development and the benefits of this approach for both smaller biotechs and their larger pharma partners.

 

 

Click here for more coverage of the activities held during BIO-Europe Spring

Previous Video
BIO-Europe Spring® 2017: Newron CEO on Xadago and upcoming pipeline milestones
BIO-Europe Spring® 2017: Newron CEO on Xadago and upcoming pipeline milestones

Newron CEO Stefan Weber discusses the company's Parkinson's therapy, Xadago (safinamide), on the eve of its...

Next Video
BIO-Europe Spring® 2017: Biomunex CSO defines lead compounds, early R&D plans
BIO-Europe Spring® 2017: Biomunex CSO defines lead compounds, early R&D plans

During BIO-Europe Spring 2017 in Barcelona, Eugene Zhukovsky, chief scientific officer at Biomunex speaks t...